Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ezetimibe. Schering-Plough.

Charles Q Meng1

  • 1AtheroGenics Inc, Alpharetta, GA 30004, USA. cmeng@atherogenics.com

Current Opinion in Investigational Drugs (London, England : 2000)
|June 11, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Carboxylated, heteroaryl-substituted chalcones as inhibitors of vascular cell adhesion molecule-1 expression for use in chronic inflammatory diseases.

Journal of medicinal chemistry·2007
Same author

Atherosclerosis is an inflammatory disorder after all.

Current topics in medicinal chemistry·2006
Same author

AGIX-4207 [2-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]acetic acid], a novel antioxidant and anti-inflammatory compound: cellular and biochemical characterization of antioxidant activity and inhibition of redox-sensitive inflammatory gene expression.

The Journal of pharmacology and experimental therapeutics·2005
Same author

Inflammation in atherosclerosis: new opportunities for drug discovery.

Mini reviews in medicinal chemistry·2005
Same author

Discovery of novel phenolic antioxidants as inhibitors of vascular cell adhesion molecule-1 expression for use in chronic inflammatory diseases.

Journal of medicinal chemistry·2004
Same author

A new era in atherosclerosis drug discovery.

Expert review of cardiovascular therapy·2004
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Ezetimibe is a novel cholesterol absorption inhibitor for treating hypercholesterolemia. It shows additive effects when combined with statins, offering a new therapeutic option.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Hypercholesterolemia is a significant risk factor for cardiovascular disease.
  • Current treatments primarily focus on statins, which inhibit cholesterol production.

Purpose of the Study:

  • To evaluate ezetimibe, a cholesterol absorption inhibitor, for hypercholesterolemia treatment.
  • To assess the potential of ezetimibe as monotherapy and in combination with statins.

Main Methods:

  • Ezetimibe (Sch-58235) development by Schering-Plough and Merck.
  • Investigating ezetimibe's mechanism: inhibiting intestinal cholesterol absorption.
  • Clinical trials studying ezetimibe monotherapy and combination therapy with statins.

Main Results:

Related Experiment Videos

  • Ezetimibe is a cholesterol absorption inhibitor.
  • Ezetimibe is being developed for hypercholesterolemia.
  • Ezetimibe is studied in combination with statins for additive lipid-lowering effects.

    • Conclusions:

    • Ezetimibe offers a novel mechanism for cholesterol management.
    • Combination therapy with statins is a key development strategy.
    • Ezetimibe is poised to be a significant new treatment for hypercholesterolemia.